Correction

Correction: Interleukin-6: a new therapeutic target

Josef S Smolen1 and Ravinder N Maini2

Author Affiliations

1 Professor of Medicine, Chairman Division of Rheumatology, Medical University of Vienna, Vienna, Austria

2 Emeritus Professor of Rheumatology, The Kennedy Institute of Rheumatology Division, Imperial College, London, UK

For all author emails, please log on.

Arthritis Research & Therapy 2006, 8:407 doi:10.1186/ar2065


The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/8/6/407


Published:17 October 2006

© 2006 BioMed Central Ltd

Correction

Following the publication of the above article [1], we noticed that due to an administrative oversight the Competing interests section was incomplete and should read as follows:

JSS has received financial compensation from and served on advisory boards for Roche and is an investigator in clinical trials of tocilizumab. RNM has received consulting fees from Chugai; served on an ad hoc advisory board for Roche; and was responsible for the planning and preparation for publication of the Phase II European (CHARISMA) trial of tocilizumab with and without methotrexate. A patent for co-administration of methotrexate and tocilizumab for the treatment of rheumatoid arthritis, of which RNM is named as a co-inventor, has been applied for and fully assigned to Chugai.

References

  1. Smolen JS, Maini RN: Interleukin-6: a new therapeutic target.

    Arthritis Res Ther 2006, 8(Suppl 2):S5. PubMed Abstract | BioMed Central Full Text OpenURL